UNITED STATES

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
D.C. 20549

|         
|---------
|FORM 10-K
|         
|         



|(Mark one)
|----------
|          
|x         

For the Fiscal
Year Ended June 30, 2012

OR

| 
|-
| 
|o

For the transition
period from _________________to

|                                 | 
|-------------------------------- | 
|Commission File Number:000-53854 | 
|                                 | 
|                                 | 

EnzymeBioSystems

(Exact name of registrant as specified
in its charter)

_________________

|Nevada                       |                                   | 27-0464302       |                    
|---------------------------- | --------------------------------- | ---------------- | -------------------
|(State or Other Jurisdiction |                                   | (I.R.S. Employer |                    
|                             | of Incorporation or Organization) |                  | Identification No.)
|                             |                                   |                  |                    



|16773 W Park Drive, Chagrin Falls, Ohio |                                          | 44023 |           
|--------------------------------------- | ---------------------------------------- | ----- | ----------
|                                        | (Address of principal executive offices) |       | (Zip Code)
|                                        |                                          |       |           



(440) 708-0012

(Registrant’s telephone number, including
area code)



Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesoNoþ



Indicate by check mark if the registrant
is not required to file reports pursuant to Section 13 or 15(d) of the Act.

YesoNoþ



Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. YesþNoo



Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YesoNooNot Applicable





Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part
III of this Form 10-K or any amendment to this Form 10-K.þ



Indicate by checkmark if disclosure of delinquent filers pursuant
to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive
proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to

this Form 10-K. [X]





|Large accelerated filero                      | Accelerated filer      | o                         |  
|--------------------------------------------- | ---------------------- | ------------------------- | -
|                                              | Non-accelerated filero | Smaller Reporting Company | þ
|(Do not check if a smaller reporting company) |                        |                           |  
|                                              |                        |                           |  





Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesoNoþ



The aggregate market value of the Company's common shares of voting
stock held by non-affiliates of the Company at April 13, 2012, computed by reference to the $3.94 per-share price quoted on the
OTC-BB was $434,306.



As of October 11, 2012, there were 31,500,000 shares of common stock,
par value $0.001 per share, of the registrant outstanding.









INDEX



|         | TITLE                                                                                      | PAGE
|-------- | ------------------------------------------------------------------------------------------ | ----
|         |                                                                                            |     
|ITEM 1.  | Business                                                                                   | 5   
|         |                                                                                            |     
|ITEM 2.  | Properties                                                                                 | 27  
|         |                                                                                            |     
|ITEM 3.  | Legal Proceedings                                                                          | 27  
|         |                                                                                            |     
|ITEM 4.  | Submission of Matters to a Vote of Security Holders                                        | 27  
|         |                                                                                            |     
|ITEM 5.  | Market for Common Equity and Related Stockholder Matters                                   | 28  
|         |                                                                                            |     
|ITEM 7.  | Management’s Discussion and Analysis of Financial Condition                                | 30  
|         |                                                                                            |     
|ITEM 8.  | Financial Statement and Supplementary Data                                                 | 33  
|         |                                                                                            |     
|ITEM 9.  | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure       | 34  
|         |                                                                                            |     
|ITEM 9A. | Controls and Procedures                                                                    | 34  
|         |                                                                                            |     
|ITEM 10. | Directors, Executive Officers and Corporate Governance                                     | 37  
|         |                                                                                            |     
|ITEM 11. | Executive Compensation                                                                     | 41  
|         |                                                                                            |     
|ITEM 12. | Security Ownership of Certain Beneficial Owners Management and Related Stockholder Matters | 43  
|         |                                                                                            |     
|ITEM 13. | Certain Relationships and Related Transactions and Director Independence                   | 44  
|         |                                                                                            |     
|ITEM 14. | Principal Accounting Fees and Services                                                     | 45  
|         |                                                                                            |     
|ITEM 15. | Exhibits, Financial Statement Schedules                                                    | 46  
|         |                                                                                            |     



2











FORWARD-LOOKING STATEMENTS



This Annual Report on Form 10-K contains forward-looking
statements. When used in this Quarterly Report on Form 10-K, the words "may," "could," "estimate,"
"intend," "continue," "believe," "expect" or "anticipate" and similar expressions
identify forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in any forward-looking
statements are reasonable, these plans, intentions, or expectations may not be achieved. Our actual results, performance, or achievements
could differ materially from those contemplated, expressed, or implied, by the forward-looking statements contained in this Annual
Report on Form 10-K. Important factors that could cause actual results to differ materially from our forward-looking statements
are set forth in this Quarterly Report on Form 10-K. Accordingly, readers are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the dates on which they are made. All forward-looking statements attributable to us or persons
acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in this Annual Report on
Form 10-K. Except as required by federal securities laws, we are under no obligation to update any forward-looking statement, whether
as a result of new information, future events, or otherwise.



Although we believe that the expectations reflected
in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed
in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking
statements, are subject to change and inherent risks and uncertainties. The factors impacting these risks and uncertainties include,
but are not limited to:



·inability to raise additional financing for working capital and product development;

·inability to identify internet marketing approaches;

·deterioration in general or regional economic, market and political conditions;

·the fact that our accounting policies and methods are fundamental to how we report our financial
condition and results of operations, and they may require management to make estimates about matters that are inherently uncertain;

·adverse state or federal legislation or regulation that increases the costs of compliance,
or adverse findings by a regulator with respect to existing operations;

·changes in U.S. GAAP or in the legal, regulatory and legislative environments in the markets
in which we operate;

·inability to efficiently manage our operations;

·inability to achieve future operating results;

·our ability to recruit and hire key employees;

·the inability of management to effectively implement our strategies and business plans; and

·the other risks and uncertainties detailed in this report.



In this form 10-K references to "EnzymeBioSystems",
"the Company", "we", "us", and "our" refer to EnzymeBioSystems.



3









AVAILABLE INFORMATION



We file annual, quarterly and special reports
and other information with the SEC. You can read these SEC filings and reports over the Internet at the SEC's website at www.sec.gov.
You can also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F
Street, NE, Washington, DC 20549 on official business days between the hours of 10:00 am and 3:00 pm. Please call the SEC at (800)
SEC-0330 for further information on the operations of the public reference facilities. We will provide a copy of our annual report
to security holders, including audited financial statements, at no charge upon receipt to of a written request to us at EnzymeBioSystems,
16773 W Park Drive, Chagrin Falls, Ohio, 44023.





























































4













PART I



ITEM 1. BUSINESS



History and Organization



The Company was organized June 26, 2009 (Date
of Inception) under the laws of the State of Nevada, as EnzymeBioSystems.





Our Business



EnzymeBioSystemsmanufactures
specialty enzymes and enzyme related products.



We utilize enzyme technologies to develop commercial
solutions for a broad range of applications within the specialty chemical industry. These markets are largely served by a small
number of large, well-established businesses and research university centers. We plan to work collaboratively with those industrial
companies to develop differentiated, high performance enzyme solutions for their target markets, and to leverage their well-developed
distribution capabilities to better exploit commercial opportunities. Our enzyme technology will tie-in with development of new
commercial biological active compounds. We hope we can develop specialty enzymes to eliminate the side effects and toxicity of
the new commercial developed products.



Our offices and laboratory is currently located
at 16773 W Park Drive, Chagrin Falls, Ohio, 44023.





Enzyme Industry



Enzymes can be categorized as "enzyme
inhibitors" and "enzyme activators." Enzyme inhibitors are molecules that bind to enzymes and decrease their activity.
Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Enzyme
activators are molecules that bind to enzymes and increase their activity. These molecules are often involved in the allosteric
[defined as having to do with a protein with a structure that is altered reversibly by a small molecule so that its original function
is modified] regulation of enzymes in the control of metabolism. Both enzyme inhibitors and enzyme activators are currently used
by many pharmaceutical and biotechnology companies in research and development of new drug compounds.







5













Enzymes also can be used as pharmaceutical
products. Enzymes as pharmaceuticals have two important features that distinguish them from all other types of pharmaceutical products.
First, enzymes often bind and act on their targets with great affinity and specificity. Second, enzymes are catalytic and convert
multiple target molecules to the desired products. These two features make are considered specialized enzymes that can accomplish
therapeutic biochemistry in the body that small molecules cannot. These characteristics have resulted in the development of many
enzyme drugs for a wide range of disorders, e.g. insulin and interferon.





Business Strategy



We foresee our three areas of business opportunity,
includes: 1) buying raw materials to produce specialty enzymes in our lab facility and offer these products for sale to research
facilities and pharmaceutical companies; 2) become a specialty contract manufacture for research universities and pharmaceutical
companies that utilize enzymes in their research programs; and, 3) Publish in research and medical journals theoretical and practical
applications of enzyme research, for the direct purpose of selling our research applications to research facilities.



We plan to deploy our enzyme technologies across
diverse markets that represent commercial opportunities in helping us build visibility for EnzymeBioSystems. This includes building
our reputation in the scientific community through trade publications and protecting our intellectual property and technology through
the patent process.



We plan to use enzyme technologies to develop
commercial solutions for a broad range of applications within the specialty chemical industry. These markets are largely served
by a small number of large, well-established businesses and research university centers. We plan to work collaboratively with those
industrial companies to develop differentiated, high performance enzyme solutions for their target markets, and to leverage their
well-developed distribution capabilities to better exploit commercial opportunities.



We currently have only limited resources and
capability to develop, manufacture, market, sell, or distribute specialty enzyme products on a commercial scale. We will determine
which specialty enzyme products to pursue independently based on various criteria, including: investment required, estimated time
to market, regulatory hurdles, infrastructure requirements, and industry-specific expertise necessary for successful commercialization.
At any time, we may modify our strategy and pursue collaborations for the development and commercialization of some specialty enzyme
products that we had intended to pursue independently. In order for us to commercialize more specialty enzyme products directly,
we plan to establish or obtain through outsourcing arrangements additional capability to develop, manufacture, market, sell, and
distribute such products.







6









Marketing Strategy



Through our future independent and collaborative
research and development programs, we plan to develop commercial enzyme products across multiple markets. In addition, we plan
to develop a pipeline of enzyme product candidates that we expect to launch independently and/or in collaboration with strategic
partners. Once we develop our innovative enzyme products, we plan to send samples of these products to potential customers. This
will give them an opportunity to evaluate our products as compared to the enzymes they are purchasing from our competition.





Competition



Our competitors have substantially greater
financial, technical, and marketing resources than we do and may succeed in developing products that would render our products
obsolete or noncompetitive. In addition, many of these competitors have significantly greater experience than we do in their respective
fields. Our ability to compete successfully will depend on our ability to develop proprietary products that reach the market in
a timely manner and are technologically superior to, and/or are less expensive than, other products on the market. Current competitors
or other companies may develop technologies and products that are more effective than ours. Our technologies and products may be
rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of our competitors.
The existing approaches of our competitors or new approaches or technology developed by our competitors may be more effective than
those developed by us.



Any enzyme products that we develop will compete
in multiple, highly competitive markets. For example, Codexis, Maxygen, Inc., Evotec, and Xencor have alternative evolution technologies.
Integrated Genomics Inc., Myriad Genetics, Inc., and ArQule, Inc. perform screening, sequencing, and/or bioinformatics services.
Novozymes A/S, Verenium Corporation, Genencor International Inc. and MPBiomedicals are involved in development, overexpression,
fermentation, and purification of enzymes. Many of these competitors have significantly greater financial and human resources than
we do. We believe that the principal competitive factors in our market are access to genetic material, technological experience
and expertise, and proprietary position.











7











Our Business Strategy



Management is preparing
a number of trade articles to publish in research and medical journals on the theoretical and practical applications of enzyme
research. Management hopes these articles will give the Company some notoriety among enzyme researchers/users. The articles are
being prepared for the direct purpose of selling our research applications to research facilities and end users. If enzyme researchers/users
are intrigued by the applications discussed in the research articles, management believes these researches/users will become future
customers and purchase specialty enzymes fromEnzymeBioSystems. Also, management hopes to position the Company, whereby
it receives royalties from the enzyme applications it develops and markets.



Management is evaluating an enzyme compound
which it believes has a specific therapeutic value in fighting tumors. In an effort to evaluate this compound, management, on or
about July 9, 2010 entered into an with Northeastern Ohio Universities College of Medicine d/b/a Northeastern Ohio Universities
Colleges of Medicine and Pharmacy in Rootstown, Ohio, to perform rat studies. The research will study a series of semisynthetic
penicillins and cephalosporins containing structural fragments of the well-known antitumor antibiotic sarcomycin. Specifically,
the two areas of this study will include: 1) an examination of the in vitrocytotoxicity of penicillin analogs against
hepatocellular carcinoma cells; and 2) Investigate the dose-responsive antitumor actions of penicillin analogs against chemically-induced
hepatic tumorigenesis in rats.



Management hopes this research with identify
an enzyme compound developed by the Company that will lead to the filing of an Investigational New Drug Application (“IND”)
with the U. S. Food and Drug Administration. It is still too early to determine if this project has any potential value for the
Company, and there are no assurances that the Company will ever obtain be able to obtain an IND for this compound.



Recent Event



The principal investigator at Northeastern
Ohio Universities College of Medicine d/b/a Northeastern Ohio Universities Colleges of Medicine and Pharmacy in Rootstown, Ohio,
assigned to the EnzymeBioSystems research project has relocated to American University of Health Sciences, Signal
Hill, CA. Management is currently working with both universities to transfer the in vivo rat studies to California, in order
for thissemisynthetic penicillins and cephalosporins research projectto be completed under
the direction of the principal investigator.







8









EnzymeBioSystems's Funding Requirements



Future funding could result in potentially
dilutive issuances of equity securities, the incurrence of debt, contingent liabilities and/or amortization expenses related to
goodwill and other intangible assets, which could materially adversely affect the Company's business, results of operations and
financial condition. Any future acquisitions of other businesses, technologies, services or product(s) might require the Company
to obtain additional equity or debt financing, which might not be available on terms favorable to the Company, or at all, and such
financing, if available,

might be dilutive.





Patent, Trademark, License and Franchise
Restrictions and Contractual Obligations and Concessions



We do not have any trademarks, patents, or
other intellectual property.



We plan to rely on trade secrets, technical
know-how, and continuing invention to develop and maintain our competitive position. We will take security measures to protect
our trade secrets, proprietary know-how and technologies, and confidential data and continue to explore further methods of protection.
Our policy is to execute confidentiality agreements with our employees and consultants upon the commencement of an employment or
consulting arrangement with us. These agreements generally require that all confidential information developed or made known to
the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to
third parties. These agreements also generally provide that inventions conceived by the individual in the course of rendering services
to us shall be our exclusive property.





Research and Development Activities and
Costs



Research and development expenses related to
our specialty enzyme business include costs related to ongoing bioprocess development and manufacturing process yield improvements.
For the fiscal year ending June 30, 2012, the Company spent $9,611 in product research and development. The research included the
development of a specialty enzyme compound that management believes will have a therapeutic value.

















9











Effect of Government Regulation on Business



We are subject to various federal, state and
local environmental laws and regulations, including those relating to the discharge of materials into the air, water and ground,
the generation, storage, handling, use, transportation and disposal of hazardous materials, and the health and safety of our employees.



Non-drug biologically derived products, such
as the specialty enzymes we plan to produce are regulated in the United States based on their application, by either the United
States Food and Drug Administration, ("FDA"), the Environmental Protection Agency, ("EPA") in the case of plants
and animals, the United States Department of Agriculture ("USDA"). In addition to regulating drugs, the FDA also regulates
food and food additives, feed and feed additives, and Generally Recognized As Safe substances used in the processing of food. The
EPA regulates biologically derived chemicals not within the FDA's jurisdiction. Although the food and industrial regulatory process
can vary significantly in time and expense from application to application, the timelines generally are shorter in duration than
the drug regulatory process.



In the United States, transgenic agricultural
products may be reviewed by the FDA, EPA, and USDA, depending on the plant and the trait engineered into it. The regulatory process
for these agricultural products can take up to five years of field testing under USDA oversight, and up to another two years for
applicable agencies to complete their reviews. At this time, we do not anticipate producing any enzymes that would require FDA
approval. Our processes would include combining enzymes that have already been approved the FDA.



Even after investing significant time and expenditures,
we may not obtain regulatory approval for our enzyme products that incorporate technologies that have not been approved for commercialization
in the United States or elsewhere. For example, the EPA regulates biologically derived chemical substances not within the FDA’s
jurisdiction. An unfavorable EPA ruling could delay commercialization or require modification of the production process resulting
in higher manufacturing costs, thereby making the product uneconomical. In addition, the USDA may prohibit genetically engineered
plants from being grown and transported except under an exemption, or under controls so burdensome that commercialization becomes
impracticable. Our future products may not be exempted by the USDA. In addition, new laws, new interpretations of existing laws,
increased governmental enforcement of environmental laws, or other developments could require us to make additional significant
expenditures.







10









We will be subject to various federal,
state and local environmental laws and regulations, including those relating to the discharge of materials into the air, water
and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials, and health and safety issues.



Outside of the United States, scientifically-based
standards, guidelines and recommendations pertinent to transgenic and other products intended for the international marketplace
are being developed by, among others, the representatives of national governments within the jurisdiction of the standard-setting
bodies, including Codex Alimentarius, the International Plant Protection Convention, and the Office des International Epizooties.
The use of the existing standard-setting bodies to address concerns about products of biotechnology is intended to harmonize risk-assessment
methodologies and evaluation of specific products or classes of products.



In the future we may be subject to additional
laws, regulations, policies, approvals and the like of federal, state, local, municipal, foreign and other bodies.





Compliance With Environmental Laws



We seek to comply with all applicable statutory
and administrative requirements concerning environmental quality. We have made, and will continue to make, expenditures for environmental
compliance and protection. Expenditures for compliance with environmental laws have not had, and are not expected to have, a material
effect on our capital expenditures, results of operation or competitive position.









































11









Employees



The Company currently has: two Officers, who
are also Directors of the Company. These two individuals perform all of the job functions for the Company. Ashot Martirosyan, our
President, devotes 40 hours per week of his time to our business, and Anushavan Yeranosyan, our Secretary/Treasurer, devotes approximately
20 hours per week of his time to our business. The Company has no intention at this time to add employees until it can become a
profitable entity. The Company from time to time may retain independent consultants in connection with its operations.



(i)The Company's performance is dependent on the performance of its officers. In particular,
the Company's success depends on their ability to develop a business strategy which will be successful for the Company.



(ii)The Company does not carry key person life insurance on any of its personnel. The loss of
the services of any of its executive officers or other key employees could have a material adverse effect on the business, results
of operations and financial condition of the Company. The Company's future success also depends on its ability to retain and attract
highly qualified technical and managerial personnel.



(iii)There can be no assurance that the Company will be able to retain its key managerial and technical
personnel or that it will be able to attract and retain additional highly qualified technical and managerial personnel in the future.
The inability to attract and retain the technical and managerial personnel necessary to support the growth of the Company's business,
due to, among other things, a large increase in the wages demanded by such personnel, could have a material adverse effect upon
the Company's business, results of operations and financial condition.































12









Item 1A. Risk Factors.





Risk Factors Relating to Our Company





RISK FACTORS RELATING TO OUR FINANCIAL CONDITION



1.
We have a limited historical financial information upon which you may evaluate our performance.



We have a limited history
and we are subject to all risks inherent in a developing business enterprise. Our likelihood of success must be considered in light
of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with manufacturing specialty
enzymes and the competitive and regulatory environment in which we operate. You should consider, among other factors, our prospects
for success in light of the risks and uncertainties encountered by companies that, like us, are in their early stages of research.
We may not successfully address these risks and uncertainties or successfully implement our operating and acquisition strategies.
If we fail to do so, it could materially harm our business to the point of having to cease operations and could impair the value
of our common stock to the point investors may lose their entire investment. Even if we accomplish these objectives, we may not
generate positive cash flows or profits we anticipate in the future.



2.
As we have never minimal revenues since our inception, there is no assurance that we will be able to continue as a going concern.



Our financial statements included with this
Annual Report for the year ended June 30, 2012, have been prepared assuming that we will continue as a going concern. Our auditors
have made reference to the substantial doubt as to our ability to continue as a going concern in their audit report on our audited
financial statements for the year ended June 30, 2012. Because the Company has been issued an opinion by its auditors that substantial
doubt exists as to whether the company can continue as a going concern, it may be more difficult for the company to attract investors.
Since our auditor’s have raised a substantial doubt about our ability to continue as a going concern, this typically results
greater difficulty to obtain loans than businesses that do not have a qualified auditors opinion. Additionally, any loans we might
obtain may be on less advantageous terms. Our future is dependent upon our ability to obtain financing and upon future profitable
operations from the sale of our future enzyme products. We plan to seek additional funds through private placements of our common
stock. You may be investing in a company that will not have the funds necessary to continue to deploy its business strategies.
If we are not able to achieve revenues or find financing, then we likely will be forced to cease operations and investors will
likely lose their entire investment, investors may lose their entire investment.

13











3.WE
MAY NOT BE ABLE TO ATTAIN PROFITABILITY WITHOUT ADDITIONAL FUNDING, WHICH MAY BE UNAVAILABLE.



We have prepared audited financial statements
for the year end for June 30, 2012, which show we cash and cash equivalents of $9,999. Our ability to continue to operate as a
going concern is fully dependent upon the Company obtaining sufficient financing to continue its development and operational activities.
The ability to achieve profitable operations is in direct correlation to our ability to generate revenues or raise sufficient financing.
It is important to note that even if the appropriate financing is received, there is no guarantee that we will ever be able to
operate profitably or derive any significant revenues from its operation. Management believes, for the next twelve months, it has
sufficient funds available to implement its business, on a limited basis.





4. IF WE ARE NOT ABLE TO COMPETE EFFECTIVELY
AGAINST LARGER BIOMEDICAL MANUFACTURERS WITH GREATER RESOURCES, OUR PROSPECTS FOR FUTURE SUCCESS WILL BE JEOPARDIZED.



We will face intense competition from larger
and better-established biomedical manufacturers that may prevent us from ever becoming a significant company. Management expects
the competition to intensify in the future. Pressures created by our future competitors could negatively impact our business, results
of operations and financial condition.



Many of our potential competitors have longer
operating histories, larger customer bases, greater brand recognition and significantly greater financial, marketing, technical
and other resources. In addition, our competitors may acquire or be acquired by, receive investments from or enter into other commercial
relationships with larger, well-established and well-financed competitors. Therefore, some of our competitors with other revenue
sources may be able to devote greater resources to marketing and promotional campaigns, adopt more aggressive pricing policies
and devote substantially more resources to product development. There can be no assurance that we will be able to compete successfully
against current and future competitors.





















14









COMPANY RISK FACTORS



5. IF WE ARE UNABLE TO RESPOND EFFECTIVELY
AS TECHNOLOGIES AND MARKET TRENDS EMERGE, OUR COMPETITIVE POSITION AND OUR ABILITY TO GENERATE REVENUES AND PROFITS MAY BE HARMED.



To be successful, we must keep pace with rapid
changes in enzyme research and technology, changing customer requirements, new innovations by competitors and evolving industry
standards, any of which could render our existing products obsolete if we fail to respond in a timely manner. For example, if new
enzyme applications are introduced by our competitors not part by our technology, or if effective new sources of enzymes are discovered,
our future products and technology could become less competitive or obsolete. If competitors develop innovative applications and
technology that is superior to ours or if we fail to accurately anticipate market trends and respond on a timely basis with our
own innovations, our potential competitive position may be harmed and we may not achieve sufficient growth in our revenues to attain,
or sustain, profitability.





6. THERE MAY BE A POSSIBLE INABILITY TO
FIND SUITABLE EMPLOYEES.



In order to implement our business plan, management
recognizes that additional staff will be required. No assurances can be given that we will be able to find suitable employees that
can support our needs or that these employees can be hired on favorable terms. We do not plan to hire any additional employees
until our cash flows can justify the expense. When we are ready to hire new employees, we will most likely look for people who
have some type of chemistry experience or a working knowledge of chemical engineering, which may be difficult to find.



7. WE MAY BE LIABLE FOR THE PRODUCTS WE
PLAN TO PRODUCE.



There is no guarantee that the level of insurance
coverage we secure will be adequate to protect us from risks associated with claims that exceed the level of coverage maintained.
As a result of our limited operations to date, no threatened or actual claims have been made upon us for product liability.















15









8. THE ENZYME COMPOUND INDUSTRY IS SUBJECT
TO PRICING PRESSURES THAT MAY CAUSE US TO REDUCE THE FUTURE GROSS MARGINS FOR OUR PRODUCTS.



If we are able to become operational management
believes to be competitive, we might be required to adjust our prices in response to industry-wide pricing pressures. Our competitors
may possibly source from regions with lower costs than those of our sourcing partners and those competitors may apply such additional
cost savings to further reduce prices.



We are not currently
operational. If we are able to become operational management believes increased customer demands for markdown allowances, incentives
and other forms of economic support might reduce our gross margins and affect our profitability. Our financial performance may
be negatively affected by these pricing pressures if we are forced to reduce our prices without being able to correspondingly reduce
our costs for finished goods or if our costs for finished goods increase and we cannot increase our prices.Management wants
investors to know that there are no assurances that we may ever achieve acceptable operating margins, we may never obtain any share
of the market, or be able to establish any value for our enzyme products.





9. THE LOSS OF ONE OR MORE OF OUR FUTURE
SUPPLIERS OF RAW MATERIALS MAY INTERRUPT OUR SUPPLIES.



We plan to purchase our raw materials from
a limited number of third-party suppliers. We do not have any material or long-term contracts in place with any suppliers at this
time. Furthermore, our future suppliers also purchase the components of our products from a limited number of suppliers. The loss
of one or more of these vendors could interrupt our supply chain and impact our ability to deliver products to our customers, which
would have a material

adverse effect on our future net sales and
profitability.





10. INCREASES IN THE PRICE OF RAW MATERIALS
USED TO MANUFACTURE OUR ENZYME PRODUCTS COULD MATERIALLY INCREASE OUR COSTS AND DECREASE OUR PROFITABILITY.



The prices for enzyme components are dependent
on the market price for the raw materials used to produce them. There can be no assurance that prices for these and other raw materials
will not increase in the near future.





16









These raw materials are subject to price volatility
caused by supply conditions, power outages, government regulations, economic climate and other unpredictable factors. Any raw material
price increase would increase our cost of sales and decrease our future profitability unless we are able to pass higher prices
on to our customers. In addition, if one or more of our competitors is able to reduce its production costs by taking advantage
of any reductions in raw material prices or favorable sourcing agreements, we may face pricing pressures from those competitors
and may be forced to reduce our prices or face a decline in net sales, either of which could have a material and adverse effect
on our business, results of operations and financial condition.



11.
We do not own equipment with the capacity to manufacture products on a commercial scale. If we are unable to access the capacity
to manufacture products in sufficient quantity, we may not be able to commercialize our products or generate significant sales.



We have only limited experience in enzyme manufacturing,
and we do not have our own internal capacity to manufacture specialty enzyme products on a commercial scale. We expect to be dependent
to a significant extent on third parties for commercial scale manufacturing of our specialty enzyme products. We do not have any
arrangements with third parties that have the required manufacturing equipment and available capacity to manufacture our commercial
enzymes. While we plan to build our own pilot development facility, we will continue to depend on third parties for large-scale
commercial manufacturing. Any difficulties or interruptions of service with our third party manufacturers or our own pilot manufacturing
facility could disrupt our research and development efforts, delay our commercialization of specialty enzyme products, and harm
our relationships with our specialty enzyme strategic partners, collaborators, or customers.





12.
We may pursue specialty enzyme products that ultimately require more resources than we anticipate or which may be technically unsuccessful.



We currently have only limited resources and
capability to develop, manufacture, market, sell, or distribute specialty enzyme products on a commercial scale. We will determine
which specialty enzyme products to pursue independently based on various criteria, including: investment required, estimated time
to market, regulatory hurdles, infrastructure requirements, and industry-specific expertise necessary for successful commercialization.
At any time, we may modify our strategy and pursue collaborations for the development and commercialization of some specialty enzyme
products that we had intended to pursue independently. We may pursue specialty





17









enzyme products that ultimately require more
resources than we anticipate or which may be technically unsuccessful. In order for us to commercialize more specialty enzyme products
directly, we would need to establish or obtain through outsourcing arrangements additional capability to develop, manufacture,
market, sell, and distribute such products. If we are unable to successfully commercialize specialty enzyme products resulting
from our internal product development efforts, we will continue to incur losses in our specialty enzymes business, as well as in
our business as a whole. Even if we successfully develop a commercial specialty enzyme product, we may not generate significant
sales and achieve profitability in our specialty enzymes business, or in our business as a whole.



13.
We may not be able to develop manufacturing capacity sufficient to meet demand in an economical manner or at all.



If demand for enzyme products increases beyond
the scope of our future production facilities, we may incur significant expenses in the expansion and/or construction of production
facilities and increases in personnel in order to increase production capacity. Any unanticipated expansion requirements may cause
complications for delays in production, which could result in a loss of business and customers. To finance the expansion of a commercial-scale
production facility is complex and expensive. We cannot assure you that we will have the necessary funds to finance the development
of production facilities, or that we will be able to develop this infrastructure in a timely or economical manner, or at all.





14.
Our officers have no experience in operating an operational specialty enzyme company, and have no experience in evaluating the
success of future products.



Our executive officers, who have chemical engineering
education, have no experience in operating a specialty enzyme Company. Their work history includes working for an antibiotic laboratory,
managing a medical supply company and working as a production engineer. They have no experience in independently developing, manufacturing,
marketing, selling, and distributing commercial specialty enzyme products. Due to their lack of experience, our executive officers
may make wrong decisions and choices regarding selection of products to pursue on behalf of the Company. Consequently, our Company
may suffer irreparable harm due to management's lack of experience in this industry. As a result we may have to suspend or cease
operations, which will result in the loss of your investment.







18









15.
We expect that certain enzyme development will require us to use hazardous materials in our business. Any claims relating to improper
handling, storage, or disposal of these materials could be time consuming and costly and could adversely affect our business and
results of operations.



Our research and development processes may
involve the controlled use of hazardous materials, including chemical, and biological materials. We cannot eliminate entirely the
risk of accidental contamination or discharge and any resultant injury from these materials. Federal, state, and local laws and
regulations govern the use, manufacture, storage, handling, and disposal of these materials. We may be sued for any injury or contamination
that results from our use or the use by third parties of these materials, and our liability may exceed our total assets. In addition,
compliance with applicable environmental laws and regulations may be expensive, and current or future environmental regulations
may impair our research, development, or production efforts. We plan to purchase insurance to protect us from potential losses;
however, at this time, we do not have any insurance coverage for accidental contamination, discharge or any resultant injury from
these hazardous materials.





16.
We are subject to all governmental rules, laws and regulations relating to the biomedicals industry in the U.S.



We are subject to all governmental rules, laws
and regulations relating to the biomedical industry in the U.S., and we fully intend to comply therewith.



Biologically derived enzyme products are regulated
in the United States based on their application, by either the United States Food and Drug Administration ("FDA"), or
the Environmental Protection Agency ("EPA"), or, in the case of plants and animals, the United States Department of Agriculture
("USDA"). In addition to regulating drugs, the FDA also regulates food and food additives, feed and feed additives, and
GRAS (Generally Recognized As Safe) substances used in the processing of food. The EPA regulates biologically derived chemicals
not within the FDA's jurisdiction.



Under current FDA policy, our future products
will most likely come within the FDA's jurisdiction, may be subject to lengthy FDA reviews and unfavorable FDA determinations if
they raise safety questions which cannot be satisfactorily answered, if results do not meet regulatory requirements or if they
are deemed to be food additives whose safety cannot be demonstrated. An unfavorable FDA ruling could be difficult to resolve and
could prevent a product from being commercialized. Even after investing significant time and expenditures, we may not obtain regulatory
approval for any drug products that incorporate our technologies or inventions.





19









The EPA regulates biologically derived chemical
substances not within the FDA's jurisdiction. An unfavorable EPA ruling could delay commercialization or require modification of
the production process resulting in higher manufacturing costs, thereby making the product uneconomical. In addition, the USDA
may prohibit genetically engineered plants from being grown and transported except under an exemption, or under controls so burdensome
that commercialization becomes impracticable. Our future products may not be exempted by the USDA.



Further, there is no assurance the governmental
agencies having jurisdiction over us, our operations and properties, will not enact laws, rules and/or regulations in the future
which may have an adverse impact on us and our operations.





17.
Our results of operations may be adversely affected by environmental, health and safety laws, regulations and liabilities.



We are subject to various federal, state and
local environmental laws and regulations, including those relating to the discharge of materials into the air, water and ground,
the generation, storage, handling, use, transportation and disposal of hazardous materials, and the health and safety of our employees.
We will need to meet a significant number of environmental and other regulations and standards established by various federal,
state and local regulatory agencies.





In addition, some of these laws and regulations
require our contemplated facilities to operate under permits that are subject to renewal or modification. These laws, regulations
and permits can often require expensive pollution control equipment or operational changes to limit actual or potential impacts
to the environment. As these regulations and standards evolve, and if new regulations or standards are implemented, we may be required
to modify our proposed facilities and processes or develop and support new facilities or processes and this will increase our costs.
Any failure to comply, or delays in compliance, with the various existing and evolving industry regulations and standards could
prevent or delay our production of specialty enzyme products. Any inability to address these requirements and any regulatory changes
could have a material adverse effect on our specialty enzyme business, financial condition and operating results.



A violation of these laws and regulations or
permit conditions can result in substantial fines, natural resource damages, criminal sanctions, permit revocations and/or facility
shutdowns.







20









18.
Our management controls a large block of our common stock that will allow them to control the Company.



As of June 30, 2012, our officers and directors
owned approximately 63% of our outstanding common stock. As a result, our two officers will have the ability to control substantially
all matters submitted to our stockholders for approval including:



a)election of our board of directors;



b)removal of any of our directors;



c)amendment of our Articles of Incorporation or bylaws; and



d)adoption of measures that could delay or prevent a change in control or impede a merger, takeover
or other business combination involving us.



As a result of their ownership
and positions, these two individuals have the ability to influence all matters requiring shareholder approval, including the election
of directors and approval of significant corporate transactions. In addition, the future prospect of sales of significant amounts
of shares held by our director and executive officer could affect the market price of our common stock if the marketplace does
not orderly adjust to the increase in shares in the market and the value of your investment in the company may decrease. Management's
stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us,
which in turn could reduce our stock price or prevent our stockholders from realizing a premium over our stock price.



Investors will own a minority percentage of
the Company’s common stock and will have minority voting rights. Investors will not have the ability to control either a
vote of the Company’s Shareholders or Board of Directors.



19.
Some of our officers and directors have other business ventures.



As disclosed in their biographies contained
herein, some of our officers and directors work with other companies in addition to their work for us. Anushavan Yeranosyan is
a part-time financial advisor of A & A Medical Supply, LLC. A & A Medical Supply distributes medical supplies to the health
care industry. Although none of our officers and directors are currently working for any other companies in the biomedical industry,
they are not prohibited from doing so.







21









Ashot Martirosyan, our President, plans to
devote 40 hours per week of his time to our business, and Anushavan Yeranosyan, our Secretary/Treasurer plans to devote 20 hours
per week of his time to our business. Anushavan Yeranosyan's other activities may prevent him from devoting full-time to our operations
which could slow our operations and may reduce our financial results because of the slow down in operations. Therefore, it is possible
that a conflict of interest with regard to his time may arise based on his involvement in other activities.



If one or more of our officers or directors
began working for another biomedical company it could take away from the time they currently spend working on our business affairs
and could create a potential conflict of interest. We do not have any employment agreements with any of your officers, which means
they are not obligated to continue to work for the Company and can resign their positions whenever they are inclined to do so.





RISK FACTORS RELATING TO OUR COMMON
STOCK AND THIS OFFERING



20.
There is no current trading market for our securities and if a trading market does not develop, purchasers of our securities may
have difficulty selling their shares.



There is currently no established public trading
market for our securities and an active trading market in our securities may not develop, or if developed, may not be sustained.
We are in the process of applying for admission to quotation of our securities on the OTC-Bulletin Board through a market maker.
If for any reason our common stock is not quoted on the OTC-Bulletin Board or a public trading market does not otherwise develop,
purchasers of the shares may have difficulty selling their common stock should they desire to do so. If no market is ever developed
for our common stock, it will be difficult for you to sell any shares you purchase in this Distribution. In such a case, you may
find that you are unable to achieve any benefit from your investment or liquidate your shares without considerable delay, if at
all. In addition, if we fail to have our common stock quoted on a public trading market, your common stock will not have a quantifiable
value and it may be difficult, if not impossible, to ever resell your shares, resulting in an inability to realize any value from
your investment.















22









21.
Future sales of shares by existing Controlling stockholders could cause our stock price to decline, FURTHER,Certain
shares of our common stock are restricted from immediate resale.





If our existing controlling
stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading
price of our common stock could decline. As of September 12, 2012, we have 31,500,000 common shares issued and outstanding. There
are 10,500,000 registered shares freely tradable, without restriction. Our officers own 20,000,000 common shares. If in the future,
if they decide to sell their shares or if it is perceived that they will be sold, to the extent permitted by the Rules 144 and
701 under the Securities Act, the trading price of our common stock could decline.



The 20,000,000 shares of common stock, owned
by our two officers are restricted from immediate resale in the public market. The restricted shares are restricted in accordance
with Rule 144, which states that if unregistered, restricted securities are to be sold, a minimum of one year must elapse between
the later of the date of acquisition of the securities from the issuer or from an affiliate of the issuer, and any resale of those
securities in reliance on Rule 144. The Rule 144 restrictive legend remains on the stock until the holder of the stock holds the
stock for longer than six months (unless an affiliate) and meets the other requirements of Rule 144 to have the restriction removed.
The sale or resale of those shares in the public market, or the market’s expectation of such sales, may result in an immediate
and substantial decline in the market price of our shares. Such a decline will adversely affect our investors, and make it more
difficult for us to raise additional funds through equity offerings in the future.



22.
We have never declared dividends on our common stock and do not plan to do so in the foreseeable future.



We intend to retain any future earnings to
finance the operation and expansion of its business and do not anticipate paying any cash dividends in the foreseeable future.
As a result, stockholders will need to sell shares of common stock in order to realize a return on their investment, if any. You
should not rely on an investment in our company if you require dividend income. The only possibility of any income to investors
would come from any rise in the market price of your stock, which is uncertain and unpredictable.



A holder of common stock will be entitled to
receive dividends only when, as, and if declared by the Board of Directors out of funds legally available therefore. We have never
issued dividends on our common stock. Our Board of Directors will determine future dividend policy based upon our results of operations,
financial condition, capital requirements, and other circumstances.





23









23.
Holders of our common stock have a risk of potential dilution if we issue additional shares of common stock in the future.



Although our Board of Directors intends to
utilize its reasonable business judgment to fulfill its fiduciary obligations to our then existing stockholders in connection with
any future issuance of our common stock, the future issuance of additional shares of our common stock would cause

immediate, and potentially substantial, dilution
to the net tangible book value of those shares of common stock that are issued and outstanding immediately prior to such transaction.
Any future decrease in the net tangible book value of our issued and outstanding shares could have a material effect on the market
value of the shares.







24.
We do not have insurance and, therefore, liability we incur could have substantial impact on our ability to continue as a going
concern.



We have limited capital and, therefore, we
do not currently have a policy of insurance against liabilities arising out of the negligence of our officers and directors and/or
arising from deficiencies in any of our business operations. Even assuming we obtained insurance, there is no assurance that such
insurance coverage would be adequate to satisfy any potential claims made against us, our officers and directors, or our business
operations or assets. Any such liability which might arise could be substantial and would likely exceed our total assets. However,
our Articles of Incorporation and Bylaws provide for indemnification of officers and directors to the fullest extent permitted
under Nevada law. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors,
officer and controlling persons, it is the opinion of the U. S. Securities and Exchange Commission that such indemnification is
against public policy, as expressed in the Act, and is therefore, unenforceable.

























24









25.
If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results
or prevent fraud and as a result, investors may be misled and lose confidence in our financial reporting and disclosures, and the
price of our common stock may be negatively affected.



The Sarbanes-Oxley Act of 2002 requires that
we report annually on the effectiveness of our internal control over financial reporting. A "significant deficiency"
means a deficiency or a combination of deficiencies, in internal control over financial reporting that is less severe than a material
weakness yet important enough to merit attention by those responsible for oversight of the Company’s financial reporting.
A "material weakness" is a deficiency or a combination of deficiencies in internal control over financial reporting,
such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not
be prevented or detected on a timely basis.



As of June 30, 2012 management assessed the
effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial
reporting. The matters involving internal controls and procedures that our management considered to be material weaknesses under
the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee due to a lack of
a majority of independent members and a lack of a majority of outside directors on our board of directors, resulting in ineffective
oversight in the establishment and monitoring of required internal controls and procedures; and (2) inadequate segregation of duties
consistent with control objectives.



In addition, in connection with our on-going
assessment of the effectiveness of our internal control over financial reporting, we may discover "material weaknesses"
in our internal controls as defined in standards established by the Public Company Accounting Oversight Board, or the PCAOB. A
material weakness is a significant deficiency, or combination of significant deficiencies, that results in more than a remote likelihood
that a material misstatement of the annual or interim financial statements will not be prevented or detected.



Failure to provide effective internal controls
may cause investors to lose confidence in our financial reporting and may negatively affect the price of our common stock. Moreover,
effective internal controls are necessary to produce accurate, reliable financial reports and to prevent fraud. If we have deficiencies
in our internal controls over financial reporting, these deficiencies may negatively impact our business and operations.









25









26.LOW-PRICED STOCKS MAY AFFECT THE RESELL OF OUR SHARES.



Penny Stock Regulation
Broker-dealer practices in connection with transactions in "Penny Stocks" are regulated by certain penny stock rules
adopted by the Securities and Exchange Commission. Penny stocks generally are equity securities with a price of less than $5.00
(other than securities registered on certain national securities exchanges or quoted on the NASDAQ system). The penny stock rules
require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized
risk disclosure document that provides information about penny stocks and the risk associated with the penny stock market. The
broker-dealer must also provide the customer with current bid and offer quotations for the penny stock, the compensation of the
broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock
held in the customer's account. In addition, the penny stock rules generally require that prior to a transaction in a penny stock;
the broker-dealer must make a written determination that the penny stock is a suitable investment for the purchaser and receive
the purchaser's written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of
trading activity in the secondary market for a stock that becomes subject to the penny stock rules. When the Registration Statement
becomes effective and the Company's securities become registered, the stock will likely have a trading price of less than $5.00
per share and will not be traded on any exchanges. Therefore, the Company's stock is initially selling at $0.01 per share they
will become subject to the penny stock rules and investors may find it more difficult to sell their securities, should they desire
to do so.











































26











Item 1B. Unresolved Staff Comments.



Not applicable.



Item 2. Properties.



Our offices are currently located at 16773
W. Park Drive, Chagrin Falls, Ohio 44023. The Company has constructed a laboratory and administrative offices at this address.
Management believes that its current facilities are adequate for its needs through the next twelve months, and that, should it
be needed, suitable additional space will be available to accommodate expansion of the Company's operations on commercially reasonable
terms, although there can be no assurance in this regard.



Item 3. Legal Proceedings.



From time to time, we may become involved in
various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent
uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.



We are not presently a party to any material
litigation, nor to the knowledge of management is any litigation threatened against us, which may materially affect us.





Item 4. Submission of Matters to a Vote of
Security Holders.



We did not submit any matters to a vote of
our security holders during the past fiscal year.



























27









PART II



Item 5. Market for Registrant's Common Equity,
Related Stockholder Matters and Issuer Purchases of Equity Securities.



(a) Market Information



EnzymeBioSystems Common Stock, $0.001 par value,
was cleared for quotation on the OTC-Bulletin Board on November 4, 2010, under the symbol: ENZB.



There are have limited trades of the Company’s
stock, since it was listed on the OTC-BB, there are no assurances that a market will ever develop for the Company's stock.



|Year ended June 30, 2012 |  | High |       |  | Low |  
|------------------------ |  | ---- | ----- |  | --- | -
|First Quarter            |  | $    | n/a   |  |     | $
|Second Quarter           |  | $    | n/a   |  |     | $
|Third Quarter            |  | $    | n/a   |  |     | $
|Fourth Quarter           |  | $    | 0.10* |  |     | $
|                         |  |     



* The first trade of the Company’s stock
took place on April 16, 2012.



(b) Holders of Common Stock



As of October 11, 2012, the Company has a total
31,500,000 common shares issued and outstanding held by approximately forty (40) shareholders.



(c) Dividends



In the future we intend to follow a policy
of retaining earnings, if any, to finance the growth of the business and do not anticipate paying any cash dividends in the foreseeable
future. The declaration and payment of future dividends on the Common Stock will be the sole discretion of board of directors and
will depend on our profitability and financial condition, capital requirements, statutory and contractual restrictions, future
prospects and other factors deemed relevant.



(d) Securities Authorized for Issuance under
Equity Compensation Plans



There are no outstanding grants or rights or
any equity compensation plan in place.



(e) Recent Sales of Unregistered Securities



The Company did not sell any stock during the
fiscal year ending June 30, 2012.



28









(f) Preferred Stock



On January 28, 2011, EnzymeBioSystems entered
into an Exclusive Technology License and Patents Agreement with Berkeley Clinic LC, an Arizona Limited Liability Company, whereby
Berkeley Clinic LC was granted:



1)an exclusive fifty (50) percent ownership in all EnymeBioSystems proprietary enzyme products;

2)the assignment of all rights, title and interest in all future patents (domestic and foreign)
granted in all enzyme products developed by EnzymeBioSystems; and,

3)and one million (1,000,000) unregistered restricted Series A Preferred shares of EnzymeBioSystems,



in exchange for One Hundred Fifty Thousand
($150,000) Dollars. The Series A Preferred Shares carry a voting weight equal to ten (10) Common Shares. The shares of Series A
Preferred Stock are not redeemable and cannot be converted into Common Shares, unless it is approved by the Board of Directors
and agreed upon by the Series A Preferred Shareholders. The Company used these funds to further capitalize the Company, and work
towards the development of proprietary enzyme products.



(g) Issuer Purchases of Equity Securities



We did not repurchase any of our equity securities
during the years ended June 30, 2012 or June 30, 2011.



Item 6. Selected Financial Data.



Not applicable.



























29











Item 7. Management's Discussion and Analysis
of Financial Condition and Results of Operations.



Overview of Current Operations



EnzymeBioSystems manufactures specialty enzymes
and enzyme related products.



Results of Operations for the year ended
June 30, 2012



We generated no revenues since our inception
on June 26, 2009 through June 30, 2012. We do not anticipate earning any significant revenues until such time as we can produce
and market specialty enzyme products. We are presently in the development stage of our business and we can provide no assurance
that we will be successful in finding a market for our specialty enzyme products.



Since our inception on June 26, 2009 through
June 30, 2012, we experienced a net loss of $(240,078). For the year ending June 30, 2012 we
lost $(70,309)as compared to a loss of $(113,975) for the same period last year. Our loss this
year was contributed to general and administrative expenses of $36,698, research and development fees of $9,611, and salaries of
$24,000. Our net loss decreased primarily due to decreased research and development costs. We anticipate our operating expenses
will increase as we build our operations.



Revenues



We generated no revenues for the period from
June 26, 2009 (inception) through June 30, 2012. We do not anticipate generating any significant revenues until we can develop
a market for our specialty enzymes.



Liquidity and Capital Resources



Our balance sheet as of June 30, 2012 reflects
current assets $9,999 and current liabilities of $25,077.



Notwithstanding, we anticipate generating losses
and therefore we may be unable to continue operations in the future. We anticipate we will require additional capital where we
would have to issue debt or equity or enter into a strategic arrangement with a third party. There can be no assurance that additional
capital will be available to us. We currently have no agreements, arrangements or understandings with any person to obtain funds
through bank loans, lines of credit or any other sources.



We believe we have sufficient cash on hand
to keep our Company fully reporting for the next twelve (12) months.



30









Future Financings



We anticipate continuing to rely on equity
sales of our common shares in order to continue to fund our business operations. Issuances of additional shares will result in
dilution to our existing shareholders. There is no assurance that we will achieve any of additional sales of our equity securities
or arrange for debt or other financing to fund our research and development activities.





Going Concern



The financial conditions evidenced by the accompanying
financial statements raise substantial doubt as to our ability to continue as a going concern. Our plans include obtaining additional
capital through debt or equity financing. The financial statements do not include any adjustments that might be necessary if we
are unable to continue as a going concern.





Summary of any product research and development
that we will perform for the term of our plan of operation.



For the fiscal year ending June 30, 2012, the
Company spent $9,611 in product research and development. The research included the development of a specialty enzyme compound
that management believes will have a therapeutic value. The compound in being tested by Northeastern Ohio Universities College
of Medicine.



Expected purchase or sale of property and
significant equipment



We do not anticipate the purchase or sale of
any property or significant equipment; as such items are not required by us at this time.



Significant changes in the number of employees



As of June 30, 2012, we did not have any employees.
We are dependent upon our sole officer and director for our future business development. As our operations expand we anticipate
the need to hire additional employees, consultants and professionals; however, the exact number is not quantifiable at this time.



Off-Balance Sheet Arrangements



We do not have any off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition,
revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material

to investors.



31









Critical Accounting Policies and Estimates



Revenue Recognition: The Company recognizes
revenue on an accrual basis as it invoices for services. Revenue is generally realized or realizable and earned when all of the
following criteria are met: 1) persuasive evidence of an arrangement exists between the Company and our customer(s); 2) services
have been rendered; 3) our price to our customer is fixed or determinable; and 4) collectability is reasonably assured.



Recent Pronouncements



The Company's management has evaluated all
the recently issued accounting pronouncements through the filing date of these financial statements and does not believe that any
of these pronouncements will have a material impact on the Company's financial position and results of operations.





Item 7A. Quantitative and Qualitative Disclosures
about Market Risk.



Not applicable.











































32











Item 8. Financial Statements and Supplementary Data.



Index to Financial Statements



|Financial Statements of EnzymeBioSystems:                                                                                                   | Page
|------------------------------------------------------------------------------------------------------------------------------------------- | ----
|Report of Independent Registered Public Accounting Firm                                                                                     | F-1 
|Balance Sheets as of June 30, 2012 and June 30, 2011                                                                                        | F-2 
|Statements of Operations for year ended June 30, 2012, June 30,
        2011 and the Period From June 26, 2009 (Inception) to June 30, 2012 | F-3 
|Statement of Stockholders' Deficit for the Period From June 26,
        2009 (Inception) to June 30, 2012                                   | F-4 
|Statement of Cash Flows for year ended June 30, 2012, June 30, 2011
        and the Period From June 26, 2009 (Inception) to June 30, 2012  | F-5 
|Notes to the Financial Statements                                                                                                           | F-6 



33







SEALE AND BEERS, CPAs

PCAOB & CPAB REGISTERED AUDITORS

www.sealebeers.com





REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM





To the Board of Directors and Stockholders
of

EnzymeBioSystems

(A Development Stage Company)



We have audited the accompanying balance sheets
of EnzymeBioSystems (A Development Stage Company) as of June 30, 2012 and 2011, and the related statements of operations, stockholders’
equity (deficit), and cash flows for the years then ended and since inception on June 26, 2009 through June 30, 2012. EnzymeBioSystems’
management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements
based on our audits.



We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of
internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our
opinion.



In our opinion, the financial statements referred to above present
fairly, in all material respects, the financial position of EnzymeBioSystems (A Development Stage Company) as of June 30, 2012
and 2011, and the related statements of operations, stockholders’ equity (deficit), and cash flows for the years then ended
and since inception on June 26, 2009 through June 30, 2012 in conformity with accounting principles generally accepted in the United
States of America.



The accompanying financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has no revenues,
has negative working capital at June 30, 2012, has incurred recurring losses and recurring negative cash flow from operating activities,
and has an accumulated deficit which raises substantial doubt about its ability to continue as a going concern. Management’s
plans concerning these matters are also described in Note 3. The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.



/s/ Seale and Beers, CPAs



Seale and Beers, CPAs

Las Vegas, Nevada

October 10, 2012



50 S. Jones Blvd. Suite 202 Las Vegas,
NV 89107 Phone: (888)727-8251 Fax: (888)782-2351



F-1











EnzymeBioSystems

(A Development Stage Company)

Balance Sheets





|                                    |                                                     |                                                  |                              | June 30, 2012              |                              | June 30, 2011
|----------------------------------- | --------------------------------------------------- | ------------------------------------------------ | ---------------------------- | -------------------------- | ---------------------------- | -------------
|                                    |                                                     | ASSETS                                           |                              |                            |                              |              
|Current assets:                     |                                                     |                                                  |                              |                           
|                                    | Cash and cash equivalents                           |                                                  | $                     9,999  |                            | $                   56,184  
|                                    |                                                     | Total current assets                             |                              | 9,999                      |                              | 56,184       
|                                    |                                                     |                                                  |                              |                            |                              |              
|TOTAL ASSETS                        |                                                     | $                     9,999                      |                              | $                   56,184
|                                    |                                                     |                                                  |                              |                            |                              |              
|                                    |                                                     | LIABILITIES AND STOCKHOLDERS' EQUITY             |                              |                            |                              |              
|Current liabilities:                |                                                     |                                                  |                              |                           
|                                    | Accounts payable                                    |                                                  | $                        387 |                            | $                        400
|                                    | Accrued expenses                                    |                                                  | 13,300                       |                            | 8,700                       
|                                    | Accrued expenses – related party                    |                                                  | 10,000                       |                            | -                           
|                                    | Credit card payable                                 |                                                  | -                            |                            | 463                         
|                                    | Due to related party                                |                                                  | 1,390                        |                            | 1,390                       
|                                    |                                                     | Total current liabilities                        |                              | 25,077                     |                              | 10,953       
|                                    |                                                     |                                                  |                              |                            |                              |              
|Stockholders' equity:               |                                                     |                                                  |                              |                           
|                                    | Preferred stock, $0.001 par value, 5,000,000 shares | 1,000                                            |                              | 1,000                     
|                                    |                                                     | authorized, 1,000,000 and 1,000,000 issued and   |                              |                            |                              |              
|                                    |                                                     | outstanding as of 6/30/12 and 6/30/11,           |                              |                            |                              |              
|                                    |                                                     | respectively                                     |                              |                            |                              |              
|                                    | Common stock, $0.001 par value, 195,000,000 shares  | 31,500                                           |                              | 31,500                    
|                                    |                                                     | authorized, 31,500,000 and 31,500,000 issued and |                              |                            |                             
|                                    |                                                     | outstanding as of 6/30/12 and 6/30/11,           |                              |                            |                              |              
|                                    |                                                     | respectively                                     |                              |                            |                              |              
|                                    | Additional paid-in capital                          |                                                  | 192,500                      |                            | 182,500                     
|                                    | Deficit accumulated during development stage        |                                                  | (240,078)                    |                            | (169,769)                   
|                                    |                                                     | Total stockholders' equity                       |                              | (15,078)                   |                              | 45,231       
|TOTAL LIABILITIES AND STOCKHOLDERS' |                                                     |                                                  |                              |                           
|                                    | EQUITY                                              |                                                  | $                     9,999  |                            | $                   56,184  





The accompanying notes are an integral part
of these financial statements.



F-2





EnzymeBioSystems

(A Development Stage Company)

Statements of Operations





|                                  |                                 |                | For the year ended June 30, 2012 |            | For the year ended June 30, 2011     |          | From June 26, 2009 (inception) to June 30, 2012
|--------------------------------- | ------------------------------- | -------------- | -------------------------------- | ---------- | ------------------------------------ | -------- | -----------------------------------------------
|Revenue                           | $                       -       |                | $                        -       |            | $                                  -
|                                  |                                 |                |                                  |            |                                      |          |                                                
|Operating expenses:               |                                 |                |                                  |            |                                     
|                                  | General & administrative        | 36,698         |                                  | 41,208     |                                      | 113,269 
|                                  | Research & development          | 9,611          |                                  | 48,767     |                                      | 74,474  
|                                  | Research & development          | -              |                                  | -          |                                      | (10,976)
|                                  |                                 | Reimbursement  |                                  |            |                                      |          |                                                
|                                  | Salaries                        | 24,000         |                                  | 24,000     |                                      | 57,000  
|                                  |                                 |                |                                  |            |                                      |          |                                                
|                                  |                                 | Total expenses | 70,309                           |            | 113,975                              |          | 233,767                                        
|                                  |                                 |                |                                  |            |                                      |          |                                                
|Loss from operations              | (70,309)                        |                | (113,975)                        |            | (233,767)                           
|                                  |                                 |                |                                  |            |                                      |          |                                                
|Other expenses:                   |                                 |                |                                  |            |                                     
|                                  | Loss on impairment of furniture | -              |                                  | -          |                                      | (6,311) 
|                                  |                                 | and equipment  |                                  |            |                                      |          |                                                
|                                  | Total other expense             | -              |                                  | -          |                                      | (6,311) 
|                                  |                                 |                |                                  |            |                                      |          |                                                
|Net (Loss)                        | $            (70,309)           |                | $          (113,975)             |            | $                    (240,078)      
|                                  |                                 |                |                                  |            |                                      |          |                                                
|Weighted average number of common |                                 |                |                                  |            |                                     
|                                  | shares outstanding- basic       | 31,500,000     |                                  | 31,500,000 |                                      |         
|                                  |                                 |                |                                  |            |                                      |          |                                                
|Net loss per share                | $                (0.00)         |                | $                (0.00)          |            |                                     





The accompanying notes are an integral part
of these financial statements.



F-3





EnzymeBioSystems

(A Development Stage Company)

Statement of Stockholders’ (Deficit)





|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  | Deficit     |  |          
|------------------------------------------------------------------ |  | --------------- |  | ------------ |  | ------------------ |  | ----------- |  | -------- |  | ----------- |  | ---------
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  | Accumulated |  |          
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  | During      |  |          
|                                                                   |  | Preferred Stock |  | Common Stock |  | Additional Paid-In |  | Development |  |         
|                                                                   |  | Shares          |  | Amount       |  | Shares             |  | Amount      |  | Capital  |  | Stage       |  | Total    
|Inception, June 26, 2009                                           |  | -               |  | -            |  | -                  |  | -           |  | -        |  | -           |  | -        
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|June 26, 2009, Contributed Capital                                 |  |                 |  |              |  |                    |  |             |  | 500      |  |             |  | 500      
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|June 29, 2009, Founders shares issued for cash at $0.001 per share |  |                 |  |              |  | 30,500,000         |  | 30,500      |  |          |  |             |  | 30,500   
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|Net (loss) for the period ending June 30, 2009                     |  |                 |  |              |  |                    |  |             |  |          |  | (3,000)     |  | (3,000)  
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|Balance, June 30, 2009                                             |  | -               |  | -            |  | 30,500,000         |  | 30,500      |  | 500      |  | (3,000)     |  | 28,000   
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|July 2009, Contributed capital (cash)                              |  |                 |  |              |  |                    |  |             |  | 2,500    |  |             |  | 2,500    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|December 2009, Contributed capital (services)                      |  |                 |  |              |  |                    |  |             |  | 2,500    |  |             |  | 2,500    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|March 26, 2010, Shares issued for cash at $0.01 per share          |  |                 |  |              |  | 1,000,000          |  | 1,000       |  | 9,000    |  |             |  | 10,000   
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|March 2010, Contributed capital (cash)                             |  |                 |  |              |  |                    |  |             |  | 2,000    |  |             |  | 2,000    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|March 2010, Contributed capital (services)                         |  |                 |  |              |  |                    |  |             |  | 2,500    |  |             |  | 2,500    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|June 2010, Contributed capital (services)                          |  |                 |  |              |  |                    |  |             |  | 2,500    |  |             |  | 2,500    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|Net (loss) for the year                                            |  |                 |  |              |  |                    |  |             |  |          |  | (52,793)    |  | (52,793) 
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|Balance, June 30, 2010                                             |  | -               |  | -            |  | 31,500,000         |  | 31,500      |  | 21,500   |  | (55,793)    |  | (2,973)  
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|August 2010, Contributed capital (cash)                            |  |                 |  |              |  |                    |  |             |  | 2,000    |  |             |  | 2,000    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|September 2010, Contributed capital (services)                     |  |                 |  |              |  |                    |  |             |  | 2,500    |  |             |  | 2,500    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|December 2010, Contributed capital (services)                      |  |                 |  |              |  |                    |  |             |  | 2,500    |  |             |  | 2,500    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|February 2011, Preferred shares issued for cash                    |  | 1,000,000       |  | 1,000        |  |                    |  |             |  | 149,000  |  |             |  | 150,000  
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|March 2011, Contributed capital (services)                         |  |                 |  |              |  |                    |  |             |  | 2,500    |  |             |  | 2,500    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|June 2011, Contributed capital (services)                          |  |                 |  |              |  |                    |  |             |  | 2,500    |  |             |  | 2,500    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|Net (loss) for the year                                            |  |                 |  |              |  |                    |  |             |  |          |  | (113,976)   |  | (113,976)
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|Balance, June 30, 2011                                             |  | 1,000,000       |  | 1,000        |  | 31,500,000         |  | 31,500      |  | 182,500  |  | (169,769)   |  | 45,231   
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|September 2011, Contributed capital (services)                     |  |                 |  |              |  |                    |  |             |  | 2,500    |  |             |  | 2,500    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|December 2011, Contributed capital (services)                      |  |                 |  |              |  |                    |  |             |  | 2,500    |  |             |  | 2,500    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|March 2012, Contributed capital (services)                         |  |                 |  |              |  |                    |  |             |  | 2,500    |  |             |  | 2,500    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|June 2012, Contributed capital (servicces)                         |  |                 |  |              |  |                    |  |             |  | 2,500    |  |             |  | 2,500    
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|Net (loss) for the year                                            |  |                 |  |              |  |                    |  |             |  |          |  | (70,309)    |  | (70,309) 
|                                                                   |  |                 |  |              |  |                    |  |             |  |          |  |             |  |          
|Balance, June 30, 2012                                             |  | 1,000,000       |  | $1,000       |  | 31,500,000         |  | $31,500     |  | $192,500 |  | $(240,078)  |  | $(15,078)





The accompanying notes are an integral part
of these financial statements.



F-4





EnzymeBioSystems

(A Development Stage Company)

Statements of Cash Flows





|                                             |                               |                      | For the year ended June 30, 2012 |  | For the year ended June 30, 2011 |  | From June 26, 2009 (inception) to June 30, 2012
|-------------------------------------------- | ----------------------------- | -------------------- | -------------------------------- |  | -------------------------------- |  | -----------------------------------------------
|OPERATING ACTIVITIES                         |                               |                      |                                  |  |                                 
|Net loss                                     | $        (70,309)             |                      | $      (113,975)                 |  | $           (240,078)           
|Adjustment to reconcile net loss to net cash |                               |                      |                                  |  |                                 
|                                             | used by operating activities: |                      |                                  |  |                                  | 
|                                             | Increase (decrease) in:       |                      |                                  |  |                                  | 
|                                             |                               | Accounts payable     | (13)                             |  | (3,073)                          |  | 387                                            
|                                             |                               | Credit card payable  | (463)                            |  | (1,020)                          |  | -                                              
|                                             |                               | Accrued expenses     | 14,600                           |  | 4,950                            |  | 23,300                                         
|                                             |                               | Depreciation         | -                                |  | -                                |  | 906                                            
|                                             |                               | Impairment of asset  | -                                |  | -                                |  | 6,311                                          
|                                             |                               | Contributed services | 10,000                           |  | 10,000                           |  | 27,500                                         
|Cash (used) in operating activities          | (46,185)                      |                      | (103,118)                        |  | (181,674)                       
|                                             |                               |                      |                                  |  |                                  |  |                                                
|INVESTING ACTIVITIES                         |                               |                      |                                  |  |                                 
|Purchase of furniture and equipment          | -                             |                      | -                                |  | (7,317)                         
|Sale of furniture and equipment              | -                             |                      | -                                |  | 100                             
|Cash (used) in investing activities          | -                             |                      | -                                |  | (7,217)                         
|                                             |                               |                      |                                  |  |                                  |  |                                                
|FINANCING ACTIVITIES                         |                               |                      |                                  |  |                                 
|Sale of preferred stock                      | -                             |                      | 150,000                          |  | 150,000                         
|Sale of common stock                         | -                             |                      | -                                |  | 40,500                          
|Contributed capital                          | -                             |                      | 2,000                            |  | 7,000                           
|Due to related party                         | -                             |                      | 1,390                            |  | 1,390                           
|Net cash provided by financing activities    | -                             |                      | 153,390                          |  | 198,890                         
|                                             |                               |                      |                                  |  |                                  |  |                                                
|NET INCREASE IN CASH                         | (46,185)                      |                      | 50,272                           |  | 9,999                           
|CASH - BEGINNING OF THE PERIOD               | 56,184                        |                      | 5,913                            |  | -                               
|CASH - END OF THE PERIOD                     | $             9,999           |                      | $           56,185               |  | $                       9,999   
|                                             |                               |                      |                                  |  |                                  |  |                                                
|SUPPLEMENTAL DISCLOSURES:                    |                               |                      |                                  |  |                                 
|Interest paid                                | -                             |                      | -                                |  | -                               
|Income taxes paid                            | -                             |                      | -                                |  | -                               
|Non-cash transactions                        | 10,000                        |                      | 10,000                           |  | 33,811                          





The accompanying notes are an integral part
of these financial statements.



F-5





EnzymeBioSystems

(A Development Stage Company)

Notes to Financial Statements

June 30, 2012 and 2011



NOTE 1 - GENERAL ORGANIZATION AND BUSINESS



EnzymeBioSystems (the "Company") was incorporated under
the laws of the state of Nevada on June 26, 2009. The Company has two officers/directors and was organized to conduct any lawful
business. The Company manufactures specialty enzymes and enzyme related products.



The Company has minimal operations and in accordance with the provisions
of the Financial Accounting Standards Board ("FASB") ASC 915, the Company is considered a development stage company.





NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES



Basis of Accounting

The basis is United States generally accepted accounting principles.



Earnings per Share

The basic earnings (loss) per share is calculated by dividing the
Company's net income (loss) available to common shareholders by the weighted average number of common shares during the year. The
diluted earnings (loss) per share is calculated by dividing the Company's net income (loss) available to common shareholders by
the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding
is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.



The Company has not issued any options or warrants or similar securities
since inception.



Dividends

The Company has not yet adopted any policy regarding payment of
dividends. No Dividends have been paid during the periods shown.



Research and development costs

Research and development costs are expensed as incurred. The amounts
of costs expensed for the years ended June 30, 2012 and 2011, were $9,611 and $48,767, respectively.



Income Taxes

The provision for income taxes is the total of the current taxes
payable and the net of the change in the deferred income taxes. Provision is made for the deferred income taxes where differences
exist between the period in which transactions affect current taxable income and the period in which they enter into the determination
of net income in the financial statements.





F-6





EnzymeBioSystems

(A Development Stage Company)

Notes to Financial Statements

June 30, 2012 and 2011





Year-end

The Company has selected June 30 as its year-end.



Advertising

Advertising is expensed when incurred. There has been no advertising
during the periods presented herein.



Use of Estimates

The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those
estimates.



Revenue recognition

The Company applies the provision of ASC 605, Revenue Recognition.
ASC 605, Revenue Recognition in Financial Statements, provides guidance on the recognition, presentation and disclosure of revenue
in financial statements. ASC 605 outlines the basic criteria that must be met to recognize revenue and provides guidance for the
disclosure of revenue recognition policies. The Company recognizes revenue related to product sales when (i) persuasive evidence
of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably
assured. For the period from June 26, 2009 (inception) to June 30, 2011, the Company has not recognized any revenues.





NOTE 3. GOING CONCERN



The accompanying financial statements have been prepared assuming
the Company will continue as a going concern. As shown in the accompanying financial statements, the Company has incurred net losses
of $(240,078) for the period from June 26, 2009 (inception) to June 30, 2012. The future of the Company is dependent upon its ability
to obtain financing and upon future profitable operations from the development of its new business opportunities.



Management has plans to seek additional capital through private
placements and public offerings of its common stock. The financial statements do not include any adjustments relating to the recoverability
and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event
the Company cannot continue in existence.



These conditions raise substantial doubt about the Company's ability
to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.





F-7





EnzymeBioSystems

(A Development Stage Company)

Notes to Financial Statements

June 30, 2012 and 2011





NOTE 4. STOCKHOLDERS'EQUITY



The Company is authorized to issue up to 5,000,000 of its $0.001
par value preferred stock and up to 195,000,000 of its $0.001 par value common stock.



Preferred Stock

On January 28, 2011, EnzymeBioSystems entered into an Exclusive
Technology License and Patents Agreement with Berkeley Clinic LC, an Arizona Limited Liability Company, whereby Berkeley Clinic
LC was granted:



1) an exclusive fifty (50) percent ownership in all EnymeBioSystems
proprietary enzyme products;

2) the assignment of all rights, title and interest in all future
patents (domestic and foreign) granted in

all enzyme products developed by EnzymeBioSystems;
and,

3) and one million (1,000,000) unregistered restricted Series A
Preferred shares of EnzymeBioSystems,



in exchange for One Hundred Fifty Thousand ($150,000) Dollars. The
Series A Preferred Shares carry a voting weight equal to ten (10) Common Shares per share of preferred stock. The shares of Series
A Preferred Stock are not redeemable and cannot be converted into Common Shares, unless it is approved by the Board of Directors
and agreed upon by the Series A Preferred Shareholders. The Company plans to use these funds to further capitalize the Company,
and develop proprietary enzyme products.





Common Stock

On June 29, 2009, the Company issued 30,500,000 shares of its $0.001
par value common stock to its nine founders for $30,500 in cash.



On March 26, 2010, the Company issued 1,000,000 shares of its $0.001
par value common stock to approximately 28 qualified investors for $10,000 in cash.



No other issuances of preferred or common stock have been made.









F-8





EnzymeBioSystems

(A Development Stage Company)

Notes to Financial Statements

June 30, 2012 and 2011





NOTE 5 - CONTRIBUTED CAPITAL



In July 2009, a director of the Company contributed capital of $2,500
for audit fees.



In March 2010, a director of the company contributed capital of
$2,000 for audit fees.



In August 2010, a director of the company contributed capital of
$2,000 for audit fees.



During the years ended June 30, 2012 and 2011, the Company's corporate
counsel agreed to prepare, write, EDGARize and provide legal opinion for the Company's interim reports and Form 10 filing. The
law firm valued these services at $10,000 for the year ended June 30, 2012 and $10,000 for the year ended June 30, 2011. The law
firm decided to contribute this capital to help build goodwill for its law firm.





NOTE 6 - RELATED PARTY TRANSACTIONS



On March 2, 2011, the Company's lawfirm paid outstanding fees due
to the company's transfer agent of $1,390. This amount remained due to the lawfirm as of June 30, 2012, and bears no interest.



The officers and directors of the Company are involved in other
business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity
becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company
has not formulated a policy for the resolution of such conflicts.



For the year ended June 30, 2012, salaries of $14,000 were paid
to an officer of the Company, as compared to salaries of $24,000 paid in the prior year. Additionally, salary of $10,000 was accrued
for the year ended June 30, 2012. The salary is paid at-will by the Company, based on available capital The
Company has no intention at this time to add employees until it can become a profitable entity.





F-9





EnzymeBioSystems

(A Development Stage Company)

Notes to Financial Statements

June 30, 2012 and 2011





NOTE 7 - PROVISION FOR INCOME TAXES



The Company accounts for income taxes under ASC 740, "Accounting
for Income Taxes", which requires use of the liability method. ASC 740 provides that deferred tax assets and liabilities are
recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting
purposes, referred to as temporary differences. Deferred tax assets and liabilities at the end of each period are determined using
the currently enacted tax rates applied to taxable income in the periods in which the deferred tax assets and liabilities are expected
to be settled or realized.



The provision for income taxes differs from the amount computed
by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the
differences are as follows:



| | U.S federal statutory rate | (35.0%)
| | -------------------------- | -------
| | Valuation reserve          | 35.0%  
| | Total                      | - %    





Income tax benefits as of June 30, 2012 and June 30, 2011, are calculated
as follows:



|                                 | 2012     | 2011    
|-------------------------------- | -------- | --------
|Deferred tax assets:             |          |         
|Net operating loss carry forward | $82,102  | $59,419 
|Less: valuation allowance        | (82,102) | (59,419)
|Net deferred tax assets          | $ -      | $ -     



During the year ended June 30, 2012, the Company recorded a valuation
allowance of $(82,102), as compared to $(59,419) for the previous year, on the deferred tax assets to reduce the total to an amount
that management believes will ultimately be realized. Realization of deferred tax assets is dependent upon sufficient future taxable
income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable
income. There was no other activity in the valuation allowance account during the year ended June 30, 2012.









F-10





EnzymeBioSystems

(A Development Stage Company)

Notes to Financial Statements

June 30, 2012 and 2011





NOTE 8 - RECENT PRONOUNCEMENTS



The Company's management has evaluated all the recently issued accounting
pronouncements through the filing date of these financial statements and does not believe that any of these pronouncements will
have a material impact on the Company's financial position and results of operations.





NOTE 9 - COMMITMENTS AND CONTINGENCIES



The Company rents its office and laboratory space in an unaffiliated,
commercially owned property for use as offices, storage and parking. The Company's current lease expires on August 31, 2015.



Minimum lease payments due under the terms of the lease are as follows:



Fiscal Year Ending

June 30, Rent

------------------ -------

2012 9,600

2013 9,600

2014 9,600

2015 9,600

2016 1,600

-------

Total $40,000



Further, on January 28, 2011, EnzymeBioSystems entered into an Exclusive
Technology License and Patents Agreement with Berkeley Clinic LC, an Arizona Limited Liability Company, whereby Berkeley Clinic
LC was granted:



1) an exclusive fifty (50) percent ownership in all EnymeBioSystems
proprietary enzyme products;

2) the assignment of all rights, title and interest in all future
patents (domestic and foreign) granted in all

enzyme products developed by EnzymeBioSystems;
and,

3) and one million (1,000,000) unregistered restricted Series A
Preferred shares of EnzymeBioSystems.









F-11





EnzymeBioSystems

(A Development Stage Company)

Notes to Financial Statements

June 30, 2012 and 2011





NOTE 10 - LONG-LIVED ASSET DEPRECIATION AND IMPAIRMENT



In October 2009, the Company placed equipment it purchased into
service. This equipment has a service life of 5 years and an estimated salvage value of 10%. Depreciation has been calculated using
the straight-line group depreciation method, whereby the cost of the fixed asset, minus the residual salvage value, is divided
by the useful life of the fixed asset.



In accordance with ASC-360-10, Accounting for the Impairment or
Disposal of Long-lived Assets, we review long-lived assets for impairment at least annually or whenever events or changes in circumstances
indicate the carrying amounts of such assets may not be recoverable. The Company's policy is to record an impairment loss at each
balance sheet date when it is determined that the carrying amount may not be recoverable. Recoverability of these assets is based
on undiscounted future cash flows of the related asset. For the year ended June 30, 2010, the Company determined that based on
estimated future cash flows, the carrying amount of our furniture and equipment exceeded its fair value by $6,311, and accordingly,
recognized an impairment loss.





NOTE 11 - RESEARCH AND DEVELOPMENT REIMBURSEMENT EXPENSES



Our research and development reimbursable costs consist primarily
of fees paid by third-parties to cover our costs to develop and manufacturer enzyme products. During the year ended June 30, 2010,
the Company was reimbursed for research and development expenses of $10,976 by the Northeastern Ohio Universities College of Medicine.
The Company has an oral agreement with the University where the Company develops and produces enzyme product(s) for the University
and is reimbursed for its actual research and development expenses related to the development of these enzyme product(s). No such
reimbursable costs occurred during the year ended June 30, 2012.





NOTE 12 - SUBSEQUENT EVENTS



The Company has evaluated subsequent events through the date that
the financial statements were issued, and has determined there are no subsequent events to be reported.





F-12









Item 9. Changes in and Disagreements With Accountants
On Accounting and Financial Disclosure.



None.



Item 9A(T). Controls and Procedures.



Evaluation of Disclosure Controls and Procedures



Our disclosure controls and procedures, as
defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are
designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded,
processed, summarized, and reported within the time periods specified in rules and forms adopted by the SEC, and that such information
is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow
timely decisions regarding required disclosures.



Management, with the participation of the Chief
Executive Officer and the Chief Financial Officer, who is also the sole member of our Board of Directors, has evaluated the effectiveness
of our disclosure controls and procedures as of the end of the period covered by this Form 10-K. Based on such evaluation, the
Chief Executive Officer and the Chief Financial Officer concluded that, as of June 30, 2011, our disclosure controls and procedures
were not effective. Our disclosure controls and procedures were not effective because of the "material weaknesses" described
below under "Management's annual report on internal control over financial reporting," which are in the process of being
remediated as described below under "Management Plan to Remediate Material Weaknesses."































34









Management's Report on Internal Control
over Financial Reporting



Our management is responsible for establishing
and maintaining adequate internal control over financial reporting. Internal control over financial reporting, as defined in rules
promulgated under the Exchange Act, is a process designed by, or under the supervision of, our Chief Executive Officer and Chief
Financial Officer and affected by our Board of Directors, management and other personnel to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.
Internal control over financial reporting includes those policies and procedures that:



·pertain to the maintenance of records that in reasonable detail accurately and fairly reflect
the transactions and dispositions of our assets;



·provide reasonable assurance that transactions are recorded as necessary to permit preparation
of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with
authorizations of our management and our Board of Directors; and



·provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use or disposition of our assets that could have a material effect on our financial statements



Because of its inherent limitations, a system
of internal control over financial reporting can provide only reasonable, not absolute, assurance that the objectives of the control
system are met and may not prevent or detect misstatements. Internal control over financial reporting is a process that involves
human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control
over financial reporting also can be circumvented by collusion or improper override. Because of such limitations, there is a risk
that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However,
these inherent limitations are known features of the financial reporting process, and it is possible to design into the process
safeguards to reduce, though not eliminate, this risk. Further, over time control may become inadequate because of changes in conditions
or the degree of compliance with the policies or procedures may deteriorate.



Our management assessed the effectiveness of
our internal control over financial reporting as of June 30, 2012. In making its assessment, management used the criteria established
in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").
Based on its assessment, management has concluded that we had certain control deficiencies described below that constituted material
weaknesses in our internal controls over financial reporting. As a result, our internal control over financial reporting was not
effective as of June 30, 2012.



35









A "material weakness" is defined
under SEC rules as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there
is a reasonable possibility that a material misstatement of a company's annual or interim financial statements will not be prevented
or detected on a timely basis by the company's internal controls. As a result of management's review of the investigation issues
and results, and other internal reviews and evaluations that were completed after the end of fiscal year ending June 30, 2012 related
to the preparation of management's report on internal controls over financial reporting required for this annual report on Form
10-K, management concluded that we had material weaknesses in our control environment and financial reporting process consisting
of the following:



1)lack of a functioning audit committee due to a lack of a majority of independent members and
a lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and
monitoring of required internal controls and procedures;



2)insufficient written policies and procedures for accounting and financial reporting with respect
to the requirements and application of US GAAP and SEC disclosure requirements; and



We do not believe the material weaknesses described
above caused any meaningful or significant misreporting of our financial condition and results of operations for the fiscal year
ended June 30, 2012. However, management believes that the lack of a functioning audit committee and the lack of a majority of
outside directors on our board of directors results in ineffective oversight in the establishment and monitoring of required internal
controls and procedures, which could result in a material misstatement in our financial statements in future periods.



Management Plan to Remediate Material Weaknesses



Management is pursuing the implementation of
corrective measures to address the material weaknesses described below. In an effort to remediate the identified material weaknesses
and other deficiencies and enhance our internal controls, we have initiated, or plan to initiate, the following series of measures:



We plan to appoint one or more outside directors
to our board of directors who shall be appointed to an audit committee resulting in a fully functioning audit committee who will
undertake the oversight in the establishment and monitoring of required internal controls and procedures such as reviewing and
approving estimates and assumptions made by management when funds are available to us.







36









We believe the remediation measures described
above will remediate the material weaknesses we have identified and strengthen our internal control over financial reporting. We
are committed to continuing to improve our internal control processes and will continue to diligently and vigorously review our
financial reporting controls and procedures. As we continue to evaluate and work to improve our internal control over financial
reporting, we may determine to take additional measures to address control deficiencies or determine to modify, or in appropriate
circumstances not to complete, certain of the remediation measures described above.



Changes in Internal Control over Financial
Reporting



There were no changes in our internal control
over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent
fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial
reporting.



This annual report does not include an attestation
report of the Corporation's registered public accounting firm regarding internal control over financial reporting. Management's
report was not subject to attestation by the Corporation's registered public accounting firm pursuant to temporary rules of the
SEC that permit the Corporation to provide only the management's report in this quarterly report.



Item 9B. Other Information.



None.









37











PART III





Item 10. Director, Executive Officer and Corporate Governance.



The following table sets forth certain information
regarding our current director and executive officer. Our executive officers serve one-year terms. Set forth below are the names,
ages and present principal occupations or employment, and material occupations, positions, offices or employments for the past
five years of our current director and executive officer.



|Name                 | Age | Position & Offices Held          
|-------------------- | --- | ---------------------------------
|                     |     |                                  
|Ashot Martirosyan    | 60  | President and Director           
|                     |     |                                  
|Anushavan Yeranosyan | 49  | Secretary, Treasurer and Director





All directors hold office until the next annual
meeting of stockholders of the Company and until their successors have been elected and qualified. Directors currently receive
no fees for services provided in that capacity. The officers of the Company are elected annually and serve at the discretion of
the Board of Directors.



Set forth below is a brief description of the
background and business experience of our sole officer and director.































37









Ashot Martirosyan, President and Director



Mr. Martirosyan was the head of the "Anti-Biotics
and Enzyme Inhibitors Laboratory" of "Institute of Organic Chemistry" in Yerevan, Armenia until November 2008. He
moved to USA November 2008 and started preparing his research results and scientific materials for publications.



Mar. 2009 –Present, President and Director of EnzymeBioSystems.



1992 - 2008 Institute of Fine Organic Chemistry,

National Academy of Sciences, Republic
of Armenia

Head of Antibiotics Laboratory



1984 – 1992 Institute of Fine Organic Chemistry,

National Academy of Sciences, Republic
of Armenia

Senior Researcher



1976 – 1984 Institute of Fine Organic Chemistry,

National Academy of Sciences, Republic
of Armenia

Antibiotics Laboratory Researcher



1974 – 1976 Optical-Mechanical Corporation – "Astro"

Head of Chemical Laboratory

Republic of Armenia





Education:



1980 – 1984 Yerevan State University

Ph.D. degree, Candidate of Chemical
Sciences: Organic Chemistry





1969 – 1974 Moscow Chemical and Technological Institute of
D.I. Mendeleev

Department of Organic Chemistry, Chemical
Technology











38









Anushavan Yeranosyan, Secretary, Treasurer and Director



2009 – Present Secretary, Treasurer and Director of EnzymeBioSystems



1996 – 2009 Cutting Systems, Inc., Cleveland, Ohio; 2002-2009,
Director of Engineering;

1998-2002, Production Manager; 1996-1998, Engineer



2005 - Present A & A Medical Supply, Euclid, Ohio, a distributor
of health care supplies,

Financial advisor





1992 – 1996 Armenian Services LLC

Yerevan, Armenia

Founder/Owner



1988 – 1992 Laser Institute, Yerevan, Armenia, 1990-1992,
Project Manager;

1988-1990, Engineer.



1984 – 1988 Aviocomplex, Yerevan, Armenia, Engineer





Education:



1987 – 1988 Moscow

Moscow Humanitarian University

Master’s Degree - International
Relations





1979 – 1984 State Engineering University of Armenia (Polytechnic)

Master’s Degree

Electronics



Section 16(a) Beneficial Ownership Reporting
Compliance



Section 16(a) of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), requires our executive officer and director, and persons who beneficially own
more than ten percent of our common stock, to file initial reports of ownership and reports of changes in ownership with the SEC.
Executive officers, directors and greater than ten percent beneficial owners are required by SEC regulations to furnish us with
copies of all Section 16(a) forms they file. Based upon a review of the copies of such forms furnished to us and written representations
from our executive officer and director, we believe that as of the date of this report they were not current in his 16(a) reports.



39







Board of Directors



Our board of directors currently consists of
two members, Ashot Martirosyan and Anushavan Yeranosyan. Our directors serve one-year terms.



Audit Committee



The company does not presently have an Audit
Committee. The sole member of the Board sits as the Audit Committee. No qualified financial expert has been hired because the company
is too small to afford such expense.



Committees and Procedures



1.	The registrant
has no standing audit, nominating and compensation committees of the Board of Directors, or committees performing similar functions.
The Board acts itself in lieu of committees due to its small size.



2.	The view
of the board of directors is that it is appropriate for the registrant not to have such a committee because its directors participate
in the consideration of director nominees and the board and the company are so small.



3.	The members
of the Board who acts as nominating committee is not independent, pursuant to the definition of independence of a national securities
exchange registered pursuant to section 6(a) of the Act (15 U.S.C. 78f(a).



4.	The nominating
committee has no policy with regard to the consideration of any director candidates recommended by security holders, but the committee
will consider director candidates recommended by security holders.



5.	The basis
for the view of the board of directors that it is appropriate for the registrant not to have such a policy is that there is no
need to adopt a policy for a small company.



6.	The nominating
committee will consider candidates recommended by security holders, and by security holders in submitting such recommendations.



7.	There
are no specific, minimum qualifications that the nominating committee believes must be met by a nominee recommended by security
holders except to find anyone willing to serve with a clean background.



8.	The nominating
committee's process for identifying and evaluation of nominees for director, including nominees recommended by security holders,
is to find qualified persons willing to serve with a clean backgrounds. There are no differences in the manner in which the nominating
committee evaluates nominees for director based on whether the nominee is recommended by a security holder, or found by the board.



40









Code of Ethics



We have not adopted a Code of Ethics for the
Board and any salaried employees.





Limitation of Liability of Directors



Pursuant to the Nevada General Corporation
Law, our Articles of Incorporation exclude personal liability for our Directors for monetary damages based upon any violation of
their fiduciary duties as Directors, except as to liability for any breach of the duty of loyalty, acts or omissions not in good
faith or which involve intentional misconduct or a knowing violation of law, or any transaction from which a Director receives
an improper personal benefit. This exclusion of liability does not limit any right which a Director may have to be indemnified
and does not affect any Director's liability under federal or applicable state securities laws. We have agreed to indemnify our
directors against expenses, judgments, and amounts paid in settlement in connection with any claim against a Director if he acted
in good faith and in a manner he believed to be in our best interests.





Nevada Anti-Takeover Law and Charter and
By-law Provisions



The anti-takeover provisions of Sections 78.411
through 78.445 of the Nevada Corporation Law apply to EnzymeBioSystems Section 78.438 of the Nevada law prohibits the Company from
merging with or selling more than 5% of our assets or stock to any shareholder who owns or owned more than 10% of any stock or
any entity related to a 10% shareholder for three years after the date on which the shareholder acquired the EnzymeBioSystems shares,
unless the transaction is approved by EnzymeBioSystems's Board of Directors. The provisions also prohibit the Company from completing
any of the transactions described in the preceding sentence with a 10% shareholder who has held the shares more than three years
and its related entities unless the transaction is approved by our Board of Directors or a majority of our shares, other than shares
owned by that 10% shareholder or any related entity. These provisions could delay, defer or prevent a change in control of EnzymeBioSystems





Item 11. Executive Compensation



The following table sets forth certain compensation
information for: (i) each person who served as the chief executive officer of our company at any time during the year ended June
30, 2012, regardless of compensation level, and (ii) each of our other executive officers, other than the chief executive officer,
serving as an executive officer at any time during 2009. The foregoing persons are collectively referred to herein as the "Named
Executive Officers." Compensation information is shown for fiscal years 2012 and 2011.



41









EnzymeBioSystems Summary Compensation Table





|                     |           |          |                     | Year   |        |       |        | Compen- |       | 
|-------------------- | --------- | -------- | ------------------- | ------ | ------ | ----- | ------ | ------- | ----- | 
|                     |           |          | Principal           | Ending | Salary | Bonus | Awards | sation  | Total | 
|Name                 | Position  | Dec. 31, | ($)                 | ($)    | ($)    | ($)   | ($)    |        
|                     |           |          |                     |        |        |       |        |         |       | 
|Ashot Martirosyan    | President | 2012     | 24,000              | 0      | 0      | 0     | 24,000 |        
|                     |           |          | 2011                | 24,000 | 0      | 0     | 0      | 24,000  |      
|                     |           |          |                     |        |        |       |        |         |       | 
|                     |           |          |                     |        |        |       |        |         |       | 
|Anushavan Yeranosyan |           |          | Secretary/Treasurer | 2012   | 0      | 0     | 0      | 0       | 0     | 
|                     |           |          |                     | 2011   | 0      | 0     | 0      | 0       | 0     | 
|                     |           |          |                    
|                     |           |          |                     |        |        |       |        |         |       | 



We do not maintain key-man life insurance for
our executive officer/director. We do not have any long-term compensation plans, stock option plans or employment agreements with
our executive officers/directors.



Stock Option Grants



We did not grant any stock options to the executive
officers or directors from inception through fiscal year end June 30, 2012.





Outstanding Equity Awards at 2012 Fiscal
Year-End



We did not have any outstanding equity awards
as of June 30, 2012 or June 30, 2011.



Option Exercises for Fiscal 2012



There were no options exercised by our named
executive officers in fiscal 2012 or 2011.



Potential Payments Upon Termination or Change
in Control



We have not entered into any compensatory plans
or arrangements with respect to our named executive officers, which would in any way result in payments to such officer(s) because
of their resignation, retirement, or other termination of employment with us or our subsidiaries, or any change in control of,
or a change in their responsibilities following a change in control.





42









Director Compensation



Our directors were not paid any compensation
during the fiscal year ending June 30, 2012 or June 30, 2011.



Item 12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters.



The following table presents information, to
the best of our knowledge, about the ownership of our common stock on October 11, 2012 relating to those persons known to beneficially
own more than 5% of our capital stock and by our named executive officer and sole director.



Beneficial ownership is determined in accordance
with the rules of the U. S. Securities and Exchange Commission and does not necessarily indicate beneficial ownership for any other
purpose. Under these rules, beneficial ownership includes those shares of common stock over which the stockholder has sole or shared
voting or investment power. It also includes shares of common stock that the stockholder has a right to acquire within 60 days
after October 11, 2012 pursuant to options, warrants, conversion privileges or other right.



The percentage ownership of the outstanding
common stock, however, is based on the assumption, expressly required by the rules of the U. S. Securities and Exchange Commission,
that only the person or entity whose ownership is being reported has converted options or warrants into shares of EnzymeBioSystems's
common stock.



We do not have any outstanding options, warrants
or other securities exercisable for or convertible into shares of our common stock.

|                                      |  |                                             |  |                                                                             
|------------------------------------- |  | ------------------------------------------- |  | ----------------------------------------------------------------------------
|Name and Address of Beneficial Owner  |  | Number of Shares
        Beneficially Owned |  | Percentage
        of Outstanding
        Shares of Common
        Stock (1)
|                                      |  |                                             |  |                                                                             
|Ashot Martirosyan (2)                 |  | 10,000,000                                  |  | 31.7%                                                                       
|                                      |  |                                             |  |                                                                             
|Anushavan Yeranosyan (3)              |  | 10,000,000                                  |  | 31.7%                                                                       
|                                      |  |                                             |  |                                                                             
|All Directors and Officers as a Group |  | 20,000,000                                  |  | 63.4%                                                                       



1)Percent of Class is based on 31,500,000shares issued and
outstanding.

2)Ashot Martirosyan, 16773 W Park Drive, Chagrin Falls, Ohio, 44023.

3)Anushavan Yeranosyan, 16773 W Park Drive, Chagrin Falls, Ohio, 44023.



43









We are not aware of any arrangements that may
result in "changes in control" as that term is defined by the provisions of Item 403(c) of Regulation S-B.



We believe that all persons named have full
voting and investment power with respect to the shares indicated, unless otherwise noted in the table. Under the rules of the Securities
and Exchange Commission, a person (or group of persons) is deemed to be a "beneficial owner" of a security if he or she,
directly or indirectly, has or shares the power to vote or to direct the voting of such security, or the power to dispose of or
to direct the disposition of such security. Accordingly, more than one person may be deemed to be a beneficial owner of the same
security. A person is also deemed to be a beneficial owner of any security, which that person has the right to acquire within 60
days, such as options or warrants to purchase our common stock.





Item 13. Certain Relationships and Related
Transactions, and Director Independence.



Our officers and directors are also our primary
shareholders. Together, our officers and directors control 20,000,000 shares of our common stock, or 63.4% of our outstanding common
stock.



Through a Board Resolution, the Company hired
the professional services of Seale and Beers, Certified Public Accountants, to perform audited financials for the Company. Seale
and Beers, CPAs own no stock in the Company. The company has no formal contracts with its accountants, as they are paid on a fee
for service basis.











































44







Item 14. Principal Accountant Fees and Services.



Seale and Beers, CPAs served as our principal
independent public accountants for reporting fiscal years ending June 30, 2012 and June 30, 2011. Aggregate fees billed to us for
the years ended June 30, 2012 and 2011 for audit fees were as follows:



|                      | For Year Ended June 30,
        2012 |  | For the Year Ended June 30,
        2011 |  |  | 
|--------------------- | ------------------------------------ |  | ---------------------------------------- |  |  | 
|(1)Audit Fees (1)     | $10,046                              |  | $9,895                                   |  |  | 
|(2)Audit-Related Fees |                                      |  |                                          |  |  | 
|(3)Tax Fees           |                                      |  |                                          |  |  | 
|(4)All Other Fees     |                                      |  |                                          |  |  | 





Total fees paid or accrued to our principal
auditor



(1) Audit Fees include fees billed and expected
to be billed for services performed to comply with Generally Accepted Auditing Standards (GAAS), including the recurring audit
of the Company's financial statements for such period included in this Annual Report on Form 10-K and for the reviews of the quarterly
financial statements included in the Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.





Audit Committee Policies and Procedures



We do not have an audit committee; therefore
our sole director pre-approves all services to be provided to us by our independent auditor. This process involves obtaining (i)
a written description of the proposed services, (ii) the confirmation of our Principal Accounting Officer that the services are
compatible with maintaining specific principles relating to independence, and (iii) confirmation from our securities counsel that
the services are not among those that our independent auditors have been prohibited from performing under SEC rules. Our sole director
then makes a determination to approve or disapprove the engagement of Seale and Beers, CPAs for the proposed services. In the fiscal
year ending June 30, 2012, all fees paid to Seale and Beers, CPAs were unanimously pre-approved in accordance with this policy.



Less than 50 percent of hours expended on the
principal accountant's engagement to audit the registrant's financial statements for the most recent fiscal year were attributed
to work performed by persons other than the principal accountant's full-time, permanent employees.



45









PART IV



Item 15. Exhibits, Financial Statement Schedules.





The following information required under this item is filed as part
of this report:



(a) 1. Financial Statements

|                                                                 | Page
|---------------------------------------------------------------- | ----
|                                                                 |     
|                                                                 |     
|Management's Report on Internal Control Over Financial Reporting | 34  
|Report of Independent Registered Public Accounting Firm          | F-1 
|Balance Sheets                                                   | F-2 
|Statements of Operations                                         | F-3 
|Statements of Stockholders' Equity                               | F-4 
|Statements of Cash Flows                                         | F-5 







(b) Financial Statement Schedules



None.





46









(c) Exhibit Index



|        |                           |                                                                                                               | Incorporated by reference |              
|------- | ------------------------- | ------------------------------------------------------------------------------------------------------------- | ------------------------- | -------------
|Exhibit | Exhibit Description       | Filed herewith                                                                                                | Form                      | Period Ending
|3.1     | Articles of Incorporation |                                                                                                               | S-1                       |              
|        | 3.2                       | By-laws as currently in effect                                                                                |                           | S-1          
|        | 3.2                       | Amended Articles of Incorporation                                                                             |                           | SB-2         
|        | 10.1                      | Agreement between EnzymeBioSystems and Northeastern Ohio Universities College of Medicine, dated July 9, 2010 |                           | 10-K         
|        | 10.2                      | Exclusive Technology License and Patents Agreement between Berkeley Clinic LC, dated January 28, 2011         |                           | 8-K          
|        | 23.1                      | Consent of Seale and Beers CPAs of June 30, 2012 financial statements                                         | X                         |              
|        | 31.1                      | Certification of Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act               | X                         |              
|        | 31.2                      | Certification of Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act               | X                         |              
|        | 32.1                      | Certification of Principal Executive Officer, pursuant to Section 906 of the Sarbanes-Oxley Act               | X                         |              
|        | 32.2                      | Certification of Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act               | X                         |              
|        |                           |                                                                                                               |                           |              







47









SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



|                        | EnzymeBioSystems
        Registrant |                                                                             
|----------------------- | ----------------------------------- | ----------------------------------------------------------------------------
|                        |                                     |                                                                             
|                        |                                     |                                                                             
|Date:  October 11, 2012 | /s/ Ashot Martirosyan               |                                                                             
|                        | Name: Ashot Martirosyan             |                                                                             
|                        |                                     | Title: President, Director
        Principal Executive Officer              
|                        |                                     |                                                                             
|Date:  October 11, 2012 | /s/ Anushavan Yeranosyan            |                                                                             
|                        | Name:  Anushavan Yeranosyan         |                                                                             
|                        |                                     | Title: Secretary/Treasurer/Director and
        Principal Accounting Officer
|                        |                                     |                                                                             



Pursuant to the requirements of the Securities Exchange Act of 1934,
the following persons on behalf of the Registrant and in the capacities and on the dates indicated have signed this report below.

|                                                              |  |                                                             |  |                 
|------------------------------------------------------------- |  | ----------------------------------------------------------- |  | ----------------
|Signature                                                     |  | Title                                                       |  | Date            
|                                                              |  |                                                             | 
|/s/ Ashot
        Martirosyan
        Ashot Martirosyan       |  | President, Director and
        Chief Executive Officer     |  | October 11, 2012
|                                                              |  |                                                             | 
|/s/ Anushavan
        Yeranosyan
        Anushavan Yeranosyan |  | Secretary, Treasurer, Director and Chief Accounting Officer |  | October 11, 2012
|                                                              |  |                                                             |  |                 



48